𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation

✍ Scribed by Maria Teresa Giordana; Carla D'Agostino; Giovanni Albani; Alessandro Mauro; Alessio Di Fonzo; Angelo Antonini; Vincenzo Bonifati

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
144 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Leucine‐Rich Repeat Kinase 2 (LRRK2) gene mutations are the most common known cause of Parkinson's disease (PD), but neuropathological studies are available on very few patients with LRRK2 mutation. The reported findings range from Lewy body–positive pathology to different pathologies, including nigral degeneration without distinctive features, neuronal loss with only ubiquitin‐positive inclusions, and tau‐positive–only pathology. Here we report the first neuropathological study in an Italian PD case carrying a different LRRK2 mutation, Ile1371Val, and showing typical ubiquitin‐ and α‐synuclein–positive Lewy body pathology. These findings support the concept that the neurodegeneration associated with LRRK2 mutations might be clinically and pathologically indistinguishable from typical PD. © 2006 Movement Disorder Society

📜 SIMILAR VOLUMES

Neuropathology of Parkinson's disease wi
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2
✍ José-Félix Martí-Massó; Javier Ruiz-Martínez; Maria J. Bolaño; Irune Ruiz; Ana G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract We report the neuropathological findings in a patient with Parkinson's disease (PD) associated with Basque R1441G‐__LRRK2__/dardarin mutation. The patient was a man with disease onset at 68 years of age, with unilateral rest tremor; the Parkinsonism was well controlled with medication f

Molecular biology changes associated wit
Molecular biology changes associated with LRRK2 mutations in Parkinson's disease
✍ Yi Wei Lu; Eng-King Tan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract Parkinson's disease (PD) is characterized by progressive dopaminergic neuronal loss in the substantia nigra. The recent discovery of __leucine‐rich‐repeat kinase 2__ gene (__LRRK2__) mutations in PD is significant because these mutations are the most common cause of autosomal dominant P

Striatal dopamine transporter binding in
Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
✍ Ioannis U. Isaias; Riccardo Benti; Stefano Goldwurm; Michela Zini; Roberto Cilia 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

We measured striatal dopamine transporter binding using [(123)I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2-PD) and in gene-negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and se

LRRK2 G2019S mutations are associated wi
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
✍ Rachel Saunders-Pullman; Matthew J. Barrett; Kaili M. Stanley; Marta San Luciano 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract Leucine rich repeat kinase (__LRRK2__) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may nonspe